Tasigna

  • Email
  • Help

Questions & Answers

On 14 September 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tasigna. The marketing authorisation holder for this medicinal product is Novartis Europharm Ltd.

The CHMP adopted an extension to the existing indication as follows:1

“Tasigna is indicated for the treatment of:

  • adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,
  • adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,
  • paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1 New text in bold

Name Language First published Last updated
CHMP post-authorisation summary of positive opinion for Tasigna (English only) 2017-09-15  

Key facts

Product details for Tasigna
NameTasigna
INN or common name

nilotinib

Therapeutic area Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Active substance

nilotinib

Date opinion adopted14/09/2017
Company name

Novartis Europharm Ltd

StatusPositive
Application typePost authorisation